Literature DB >> 8549885

Immunohistochemical distribution and serum levels of the Ca(2+)-binding proteins MRP8, MRP14 and their heterodimeric form MRP8/14 in Crohn's disease.

N Lügering1, R Stoll, T Kucharzik, K W Schmid, G Rohlmann, G Burmeister, C Sorg, W Domschke.   

Abstract

In previous histochemical studies the distribution of the two Ca(2+)-binding proteins MRP8 and MRP14 as well as their heterocomplex MRP8/14 has been demonstrated in different inflammatory diseases. Monoclonal antibodies against MRP8 and MRP14 and their heterodimer MRP8/14 (27E10 epitope) were used to investigate immunohistochemically the distribution of these proteins in routinely processed small and large bowel tissues from patients with Crohn's disease (CD). Furthermore, we used a sandwich immunoassay to measure serum concentrations of MRPs in 62 patients were simultaneously assessed by the Crohn's disease activity index (CDAI) and the severity activity index of Goebell (SAI). In our immunohistochemical study, MRP8, MRP14 and heterocomplex MRP8/14 were demonstrated in the majority of granulocytes and macrophages in active CD. Additionally, a strong complex MRP8/14 immunoreactivity was present in epithelial cells adjacent to ulcerative and fissuring lesions in the bowel. Serum MRP8/14 concentrations were significantly (p < 0.0001) increased in patients with active CD (CDAI > 150, SAI > 120). No correlations were found for level of MRP14 and MRP8 alone, respectively. The follow-up of individual patients with initially active CD showed a further increase in MRP8/14 levels during acute attacks of the inflammatory process. We suggest that our assay for MRP8/14 discriminates well between active and inactive CD and may have considerable potential in the analysis of clinical disease activity in CD patients. Our morphological results confirm the finding of increased MRP8/14 serum levels in patients with active CD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8549885     DOI: 10.1159/000201267

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  34 in total

1.  Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.

Authors:  T Kaiser; J Langhorst; H Wittkowski; K Becker; A W Friedrich; A Rueffer; G J Dobos; J Roth; D Foell
Journal:  Gut       Date:  2007-08-03       Impact factor: 23.059

2.  S100 calgranulin proteins S100A8, S100A9 and S100A12 are expressed in the inflamed gastric mucosa of Helicobacter pylori-infected children.

Authors:  Steven T Leach; Hazel M Mitchell; Carolyn L Geczy; Philip M Sherman; Andrew S Day
Journal:  Can J Gastroenterol       Date:  2008-05       Impact factor: 3.522

Review 3.  Functional and clinical aspects of the myelomonocyte protein calprotectin.

Authors:  B Johne; M K Fagerhol; T Lyberg; H Prydz; P Brandtzaeg; C F Naess-Andresen; I Dale
Journal:  Mol Pathol       Date:  1997-06

4.  Synergistic effect of immunoregulatory cytokines on peripheral blood monocytes from patients with inflammatory bowel disease.

Authors:  T Kucharzik; N Lügering; M Adolf; W Domschke; R Stoll
Journal:  Dig Dis Sci       Date:  1997-04       Impact factor: 3.199

5.  S100A8 triggers oxidation-sensitive repulsion of neutrophils.

Authors:  H Y Sroussi; J Berline; P Dazin; P Green; J M Palefsky
Journal:  J Dent Res       Date:  2006-09       Impact factor: 6.116

Review 6.  Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease.

Authors:  Anastassios C Manolakis; Andreas N Kapsoritakis; Elisavet K Tiaka; Spyros P Potamianos
Journal:  Dig Dis Sci       Date:  2011-01-04       Impact factor: 3.199

Review 7.  Nutritional Immunity: S100 Proteins at the Host-Pathogen Interface.

Authors:  Joseph P Zackular; Walter J Chazin; Eric P Skaar
Journal:  J Biol Chem       Date:  2015-06-08       Impact factor: 5.157

8.  IL-1 receptor regulates S100A8/A9-dependent keratinocyte resistance to bacterial invasion.

Authors:  B S Sorenson; A Khammanivong; B D Guenther; K F Ross; M C Herzberg
Journal:  Mucosal Immunol       Date:  2011-10-26       Impact factor: 7.313

9.  Treatment with anti-NAP monoclonal antibody reduces disease severity in murine model of novel angiogenic protein-induced or ovalbumin-induced arthritis.

Authors:  N B Nataraj; J Krishnamurthy; B P Salimath
Journal:  Clin Exp Immunol       Date:  2013-02       Impact factor: 4.330

10.  Transcript levels of different cytokines and chemokines correlate with clinical and endoscopic activity in ulcerative colitis.

Authors:  Alexandra Zahn; Thomas Giese; Max Karner; Annika Braun; Ulf Hinz; Wolfgang Stremmel; Robert Ehehalt
Journal:  BMC Gastroenterol       Date:  2009-02-09       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.